# Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

> **NCT00809250** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 33 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts

## Interventions

- **BIOLOGICAL:** GM-K562/leukemia cell vaccine

## Key facts

- **NCT ID:** NCT00809250
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-05
- **Final completion:** 2020-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00809250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00809250, "Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00809250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*